Status:
ACTIVE_NOT_RECRUITING
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
Lead Sponsor:
University of Alberta
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
This study is a single centre non-randomized non-blinded phase II prospective cohort study including 50 participants. The objective of this study is to directly compare 68Ga-HA-DOTATATE, 18F-DOPA, and...
Eligibility Criteria
Inclusion
- History of biopsy proven neuroendocrine tumor including (but not limited to): gastrointestinal NET, pancreatic NET, pulmonary NET, NET unknown primary, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma
- At least two abnormal 68Ga-HA-DOTATATE positive lesions suspected to represent neuroendocrine tumor (at least tow lesions with SUVmax \> SUV meanliver).
- Age greater or equal to 40
- Ability to provide written informed consent prior to participation in the study
Exclusion
- Weight \> 225 kg (weight limitation of PET/CT scanner)
- Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging
- Any medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation
- Previous allergic reaction to 18F-DOPA
- Lack of intravenous access
- Pregnant
- Breastfeeding
- Less than 40 years old
Key Trial Info
Start Date :
October 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05255159
Start Date
October 15 2022
End Date
June 30 2026
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7